We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Original Investigation |

Association of GBA Mutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease ONLINE FIRST

Marie Y. Davis, MD, PhD1,2; Catherine O. Johnson, PhD, MPH2; James B. Leverenz, MD3; Daniel Weintraub, MD4; John Q. Trojanowski, MD, PhD5; Alice Chen-Plotkin, MD6; Vivianna M. Van Deerlin, MD, PhD5; Joseph F. Quinn, MD7,8; Kathryn A. Chung, MD7,8; Amie L. Peterson-Hiller, MD7,8; Liana S. Rosenthal, MD9,10; Ted M. Dawson, MD, PhD9,10,11,12; Marilyn S. Albert, PhD10; Jennifer G. Goldman, MD, MS13; Glenn T. Stebbins, PhD13; Bryan Bernard, PhD13; Zbigniew K. Wszolek, MD14; Owen A. Ross, PhD15; Dennis W. Dickson, MD15; David Eidelberg, MD16,17; Paul J. Mattis, PhD16,17; Martin Niethammer, MD, PhD16; Dora Yearout, BS1,2; Shu-Ching Hu, MD, PhD1,2; Brenna A. Cholerton, PhD1,18; Megan Smith, PhD20; Ignacio F. Mata, PhD1,2; Thomas J. Montine, MD, PhD19; Karen L. Edwards, PhD20; Cyrus P. Zabetian, MD, MS1,2
[+] Author Affiliations
1Veterans Affairs Puget Sound Health Care System, Seattle, Washington
2Department of Neurology, University of Washington School of Medicine, Seattle
3Lou Ruvo Center for Brain Health, Neurological Institute, Cleveland Clinic, Cleveland, Ohio
4Department of Psychiatry, University of Pennsylvania, Philadelphia
5Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia
6Department of Neurology, University of Pennsylvania, Philadelphia
7Portland Veterans Affairs Medical Center, Portland, Oregon
8Department of Neurology, Oregon Health and Science University, Portland
9Neurodegeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland
10Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland
11Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, Maryland
12Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland
13Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois
14Department of Neurology, Mayo Clinic, Jacksonville, Florida
15Department of Neuroscience, Mayo Clinic, Jacksonville, Florida
16Center for Neurosciences, Feinstein Institute for Medical Research, Manhasset, New York
17Department of Neurology, Northwell Health, Manhasset, New York
18Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle
19Department of Pathology, University of Washington School of Medicine, Seattle
20Department of Epidemiology, University of California, Irvine, School of Medicine
JAMA Neurol. Published online August 29, 2016. doi:10.1001/jamaneurol.2016.2245
Text Size: A A A
Published online

Importance  Parkinson disease (PD) is heterogeneous in symptom manifestation and rate of progression. Identifying factors that influence disease progression could provide mechanistic insight, improve prognostic accuracy, and elucidate novel therapeutic targets.

Objective  To determine whether GBA mutations and the E326K polymorphism modify PD symptom progression.

Design, Setting, and Participants  The entire GBA coding region was screened for mutations and E326K in 740 patients with PD enrolled at 7 sites from the PD Cognitive Genetics Consortium. Detailed longitudinal motor and cognitive assessments were performed with patients in the on state.

Main Outcomes and Measures  Linear regression was used to test for an association between GBA genotype and motor progression, with the Movement Disorder Society–sponsored version of the Unified Parkinson’s Disease Rating Scale Part III (MDS-UPDRS III) score at the last assessment as the outcome and GBA genotype as the independent variable, with adjustment for levodopa equivalent dose, sex, age, disease duration, MDS-UPDRS III score at the first assessment, duration of follow-up, and site. Similar methods were used to examine the association between genotype and tremor and postural instability and gait difficulty (PIGD) scores. To examine the effect of GBA genotype on cognitive progression, patients were classified into those with conversion to mild cognitive impairment or dementia during the study (progression) and those without progression. The association between GBA genotype and progression status was then tested using logistic regression, adjusting for sex, age, disease duration, duration of follow-up, years of education, and site.

Results  Of the total sample of 733 patients who underwent successful genotyping, 226 (30.8%) were women and 507 (69.2%) were men (mean [SD] age, 68.1 [8.8] years). The mean (SD) duration of follow-up was 3.0 (1.7) years. GBA mutations (β = 4.65; 95% CI, 1.72-7.58; P = .002), E326K (β = 3.42; 95% CI, 0.66-6.17; P = .02), and GBA variants combined as a single group (β = 4.01; 95% CI, 1.95-6.07; P = 1.5 × 10−4) were associated with a more rapid decline in MDS-UPDRS III score. Combined GBA variants (β = 0.38; 95% CI, 0.23-0.53; P = .01) and E326K (β = 0.64; 95% CI, 0.43-0.86; P = .002) were associated with faster progression in PIGD scores, but not in tremor scores. A significantly higher proportion of E326K carriers (10 of 21 [47.6%]; P = .01) and GBA variant carriers (15 of 39 [38.5%]; P = .04) progressed to mild cognitive impairment or dementia.

Conclusions and Relevance  GBA variants predict a more rapid progression of cognitive dysfunction and motor symptoms in patients with PD, with a greater effect on PIGD than tremor. Thus, GBA variants influence the heterogeneity in symptom progression observed in PD.





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

Articles Related By Topic
Related Collections
PubMed Articles

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis

The Rational Clinical Examination: Evidence-Based Clinical Diagnosis
Make the Diagnosis: Parkinsonism